Company news

Insmed Incorporated news in 2020

Insmed Incorporated's news releases, calls and decks from 2020, newest first.

View company

Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

December 1, 2020

Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference

November 23, 2020

Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

November 12, 2020

Insmed to Present at Two November Conferences

November 1, 2020

Insmed Reports Third Quarter 2020 Financial Results and Provides Business Update

October 28, 2020

European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options

October 27, 2020

Insmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020

October 19, 2020

Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day

September 29, 2020

Insmed to Host R&D Day on September 30, 2020

September 15, 2020

Insmed to Present at Three September Conferences

September 8, 2020

New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis

September 6, 2020

Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update

August 5, 2020

Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020

July 26, 2020

Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options

July 23, 2020

New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease

July 6, 2020

Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session

June 23, 2020

Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

June 7, 2020

Insmed to Present at Two June Conferences

May 25, 2020

Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session

May 19, 2020

Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

May 6, 2020

Insmed Announces Pricing of Public Offering of Common Stock

May 4, 2020

Insmed Announces Proposed Public Offering of Common Stock

May 3, 2020

Insmed Reports First Quarter 2020 Financial Results and Provides Business Update

April 29, 2020

Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial

April 22, 2020

Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020

April 19, 2020

Insmed Appoints Carol A. Schafer to its Board of Directors

April 1, 2020

Insmed Provides Business Update

March 15, 2020

Insmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal Open Forum Infectious Disease

March 3, 2020

Insmed to Present at the Cowen and Company 40th Annual Health Care Conference

February 25, 2020

Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

February 24, 2020

Insmed to Present at the 9th Annual SVB Leerink Global Healthcare Conference

February 18, 2020

Insmed to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, February 25, 2020

February 9, 2020

Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis

February 2, 2020

Insmed Appoints Sara Bonstein as Chief Financial Officer

January 29, 2020

Calls in 2020

Decks in 2020